| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.1 | 7.0 |
| Profit before tax | -6.4 | -6.6 |
| Net income | -6.4 | -6.6 |
| EPS (diluted, $ a share) | $-0.42 | $-0.62 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +29.8% |
|---|---|
| Operating margin | -71.6% |
10-Q filed with the SEC, NASDAQ: BFRI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Biofrontera Inc.: key numbers
- Share price
- $0.5700Close, Nov 16
- Market cap
- $10.2M
- Shares outstanding
- 17.95MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biofrontera Inc.
All →Biofrontera Financial Results
Biofrontera Inc. reported Q3 2026 net product revenue of $9.1 million, a 30% year-over-year increase driven by its photodynamic therapy products. The company achieved a significant regulatory milestone with the FDA approval of Ameluz for the treatment of superficial basal cell carcinoma. Net loss for the quarter narrowed slightly to $6.4 million compared to $6.6 million in the prior-year period.
- Term
- Q3 2026
“The third quarter was a pivotal one for Biofrontera. On September 9, the FDA approved Ameluz® PDT for the treatment of superficial basal cell carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that our redesigned RhodoLED® XL-C is not subject to the ITC exclusion order, which allows us to again serve the customers who rely on our large-field lamp.”
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera
Biofrontera Regulatory Approval
Biofrontera received FDA approval for its supplemental New Drug Application (sNDA) for Ameluz in combination with the BF-RhodoLED lamp series to treat superficial basal cell carcinoma. This marks the first and only photodynamic therapy approved in the U.S. for a skin cancer, significantly expanding the addressable market for the company's PDT platform.
“FDA approval of Ameluz for superficial basal cell carcinoma is a defining milestone for Biofrontera. Ameluz is now the first and only photodynamic therapy approved in the United States to treat a skin cancer, which sets our platform apart in medical dermatology and gives dermatologists an effective, non-surgical option for a very common tumor.”
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera